AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $321.34 billion. The enterprise value is $345.43 billion.
Important Dates
The last earnings date was Tuesday, February 10, 2026, before market open.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 64.53% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 31.81 and the forward PE ratio is 39.79.
| PE Ratio | 31.81 |
| Forward PE | 39.79 |
| PS Ratio | 5.47 |
| Forward PS | 5.06 |
| PB Ratio | 6.60 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 27.31 |
| P/OCF Ratio | 22.05 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 17.72, with an EV/FCF ratio of 29.36.
| EV / Earnings | 33.78 |
| EV / Sales | 5.88 |
| EV / EBITDA | 17.72 |
| EV / EBIT | 24.71 |
| EV / FCF | 29.36 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.61.
| Current Ratio | 0.94 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 1.52 |
| Debt / FCF | 2.52 |
| Interest Coverage | 8.25 |
Financial Efficiency
Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is 16.12%.
| Return on Equity (ROE) | 22.84% |
| Return on Assets (ROA) | 8.01% |
| Return on Invested Capital (ROIC) | 16.12% |
| Return on Capital Employed (ROCE) | 16.75% |
| Weighted Average Cost of Capital (WACC) | 5.26% |
| Revenue Per Employee | $632,282 |
| Profits Per Employee | $110,065 |
| Employee Count | 92,900 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.82 |
Taxes
In the past 12 months, AstraZeneca has paid $2.17 billion in taxes.
| Income Tax | 2.17B |
| Effective Tax Rate | 17.49% |
Stock Price Statistics
The stock price has increased by +45.57% in the last 52 weeks. The beta is 0.19, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +45.57% |
| 50-Day Moving Average | 188.68 |
| 200-Day Moving Average | 162.08 |
| Relative Strength Index (RSI) | 63.65 |
| Average Volume (20 Days) | 2,093,112 |
Short Selling Information
The latest short interest is 12.27 million, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 12.27M |
| Short Previous Month | 8.32M |
| Short % of Shares Out | 0.79% |
| Short % of Float | 0.79% |
| Short Ratio (days to cover) | 2.25 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $58.74 billion and earned $10.23 billion in profits. Earnings per share was $6.54.
| Revenue | 58.74B |
| Gross Profit | 47.97B |
| Operating Income | 13.98B |
| Pretax Income | 12.40B |
| Net Income | 10.23B |
| EBITDA | 19.50B |
| EBIT | 13.98B |
| Earnings Per Share (EPS) | $6.54 |
Full Income StatementBalance Sheet
The company has $5.74 billion in cash and $29.70 billion in debt, with a net cash position of -$23.96 billion or -$15.45 per share.
| Cash & Cash Equivalents | 5.74B |
| Total Debt | 29.70B |
| Net Cash | -23.96B |
| Net Cash Per Share | -$15.45 |
| Equity (Book Value) | 48.72B |
| Book Value Per Share | 31.38 |
| Working Capital | -1.89B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $14.58 billion and capital expenditures -$2.81 billion, giving a free cash flow of $11.77 billion.
| Operating Cash Flow | 14.58B |
| Capital Expenditures | -2.81B |
| Free Cash Flow | 11.77B |
| FCF Per Share | $7.59 |
Full Cash Flow StatementMargins
Gross margin is 81.66%, with operating and profit margins of 23.80% and 17.41%.
| Gross Margin | 81.66% |
| Operating Margin | 23.80% |
| Pretax Margin | 21.11% |
| Profit Margin | 17.41% |
| EBITDA Margin | 33.19% |
| EBIT Margin | 23.80% |
| FCF Margin | 20.03% |
Dividends & Yields
This stock pays an annual dividend of $3.20, which amounts to a dividend yield of 1.54%.
| Dividend Per Share | $3.20 |
| Dividend Yield | 1.54% |
| Dividend Growth (YoY) | 3.23% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 48.93% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 1.60% |
| Earnings Yield | 3.18% |
| FCF Yield | 3.66% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 7.36% |
| EPS Growth Forecast (5Y) | 4.67% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.21 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.21 |
| Piotroski F-Score | 7 |
